Compare LRMR & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LRMR | SOPH |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.8M | 462.3M |
| IPO Year | 2014 | 2021 |
| Metric | LRMR | SOPH |
|---|---|---|
| Price | $3.92 | $7.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $16.50 | $7.50 |
| AVG Volume (30 Days) | ★ 857.9K | 518.9K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $23.09 |
| Revenue Next Year | $1,816.14 | $19.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $3.10 |
| 52 Week High | $6.42 | $8.98 |
| Indicator | LRMR | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 44.77 | 47.88 |
| Support Level | $3.57 | $4.57 |
| Resistance Level | $4.21 | $7.88 |
| Average True Range (ATR) | 0.19 | 0.50 |
| MACD | -0.03 | -0.17 |
| Stochastic Oscillator | 20.39 | 5.19 |
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.